12:00 AM
Mar 19, 2012
 |  BC Week In Review  |  Clinical News  |  Regulatory

Binosto regulatory update

FDA approved an NDA for Binosto alendronate from EffRx to treat osteoporosis. EffRx will launch the alendronate effervescent tablets in the U.S. in 3Q12. EffRx has exclusive, worldwide rights to IP covering...

Read the full 136 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >